Vexing vaccine delays hit drug firms

AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.

Drug companies AstraZeneca and Pfizer are being attacked by the EU over vaccine delivery delays that could slow the EU’s recovery from Covid-19, says Julia Horowitz on CNN. Pfizer’s problems look likely to be resolved soon, however, while AstraZeneca says “considerably fewer” doses will be supplied for some time. With AstraZeneca’s jab due to be approved by Europe’s regulator shortly, “mounting” anger means that Brussels and several countries are “threatening to take legal action and introduce export controls on doses produced in the bloc” (see page 8).

AstaZeneca’s announcement will prolong the “misery and pain” of Covid-19, says Aimee Donnellan on Breakingviews. Still, problems were “inevitable” as the vaccine, developed by the University of Oxford, is made “through a complicated biological process, requiring constant fine-tuning and vast 4,000-litre fermenters, which are in short supply”.

AstraZeneca’s problems are good news for the jab produced by Janssen, Johnson & Johnson’s European vaccine division, which the EU has pre-ordered in large amounts, says the Irish Times. Like the AstraZeneca jab, it doesn’t require “ultra-cold storage temperatures”; but unlike all its major competitors, it also involves a single injection, “greatly simplifying... a national vaccine rollout”. With trial data expected in the next few days, the vaccine is set to receive approval from the US Food and Drug Administration sometime in February, with the nod from the European Medicines Agency expected not long afterwards. 

Recommended

When investors get over-excited, it’s time to worry – but we’re not there yet
Sponsored

When investors get over-excited, it’s time to worry – but we’re not there yet

When investors are pouring money into markets, it can be a warning sign of impending disaster, writes Max King. So how are fund flows looking right no…
26 Oct 2021
An investment trust that gives exposure to frontier markets
Investment trusts

An investment trust that gives exposure to frontier markets

An investment trust investing in small, illiquid emerging markets has disappointed, but deserves another chance, says Max King
26 Oct 2021
What does Rishi Sunak have in store for investors this Wednesday?
Budget

What does Rishi Sunak have in store for investors this Wednesday?

Rishi Sunak is unveiling his spending plans for the economy this week. John Stepek analyses areas which may be most hit by the budget.
25 Oct 2021
How rising interest rates could hurt big tech stocks
Tech stocks

How rising interest rates could hurt big tech stocks

Low interest rates have helped the biggest companies to entrench their positions. But what if rates rise?
25 Oct 2021

Most Popular

Properties for sale for around £1m
Houses for sale

Properties for sale for around £1m

From a stone-built farmhouse in the Snowdonia National Park, to a Victorian terraced house close to London’s Regent’s Canal, eight of the best propert…
15 Oct 2021
How to invest as we move to a hydrogen economy
Energy

How to invest as we move to a hydrogen economy

The government has started to roll out its plans for switching us over from fossil fuels to hydrogen and renewable energy. Should investors buy in? St…
8 Oct 2021
Emerging markets: the Brics never lived up to their promise – but is now the time to buy?
Emerging markets

Emerging markets: the Brics never lived up to their promise – but is now the time to buy?

Twenty years ago hopes were high for Brazil, Russia, India and China – the “Brics” emerging-market economies. But only China has beaten expectations. …
18 Oct 2021